Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit .
Why this byte is shareable
Signal quality
observed
Confidence badge and source context included.
Entity anchor
AI News
Clear company or model context for distribution.
Export ready
1200 x 630 card
Optimized for X, LinkedIn, and chat previews.
Why it matters
AI News can change capability, routing, cost, or product scope for builders shipping against current model APIs.
Suggested launch post
Use this in X threads, community posts, internal team chats, or launch recaps.
Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit Why it matters: AI News can change capability, routing, cost, or product scope for builders shipping against current model APIs. Source: Financialcontent https://a2zai.ai/bytes/simulations-p...
Permalink: https://a2zai.ai/bytes/simulations-plus-advances-agentic-drug-development-with-nvidia-bionemo-agent-too-4d919f35
Social card: https://a2zai.ai/bytes/simulations-plus-advances-agentic-drug-development-with-nvidia-bionemo-agent-too-4d919f35/opengraph-image